The Meaning of SARS-CoV-2 Antibodies in a Patient with a Systemic Reaction to the mRNA-1273 SARS-CoV-2 Vaccine after Previous Natural Immunization

  • Lorraine Sazgary Medical Outpatient Clinic, University Hospital Basel, University of Basel, Basel, Switzerland
  • Andrea Meienberg Medical Outpatient Clinic, University Hospital Basel, University of Basel, Basel, Switzerland
  • Christoph T Berger Medical Outpatient Clinic, University Hospital Basel, University of Basel, Basel, Switzerland
  • Michael Mayr Medical Outpatient Clinic, University Hospital Basel, University of Basel, Basel, Switzerland

Keywords

COVID-19, vaccine, immune-reactivity, SARS-CoV-2 nucleocapsid antibody, SARS-CoV-2 spike antibody

Abstract

Objectives: There is limited experience regarding the meaning of SARS-CoV-2 antibodies after vaccination in patients with naturally acquired immunity.

Methods: We describe the case of a patient who received the first dose of the mRNA-1273 SARS-CoV-2 vaccine 6 months after his recovery from moderately severe COVID-19.

Results: Our patient had a positive nucleocapsid SARS-CoV-2 IgG/IgM titre with 78.7 multiple of cut-off indicating persistent humoral immune response 6 months after infection. After vaccination, he developed prolonged systemic symptoms (fever, fatigue, nausea, diarrhoea and myalgia) for a duration of 6 days.

Conclusion: SARS-CoV-2 nucleocapsid antibodies provide information about naturally acquired immunity. For the assessment of immune response to vaccination, measurement of the SARS-CoV-2 spike antibody titre before and after vaccination is essential. Patients with naturally acquired immunity might develop a prolonged systemic reaction to the first dose of the mRNA-1273 SARS-CoV-2 vaccine.

VIEW THE ENTIRE ARTICLE

References

  • Masters PS. The molecular biology of coronaviruses. Adv Virus Res 2006;65:193–292. doi:10.1016/S0065-3527(06)66005-3
  • Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 2021;371(6529):eabf4063. doi:10.1126/science.abf4063
  • Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021;384(5):403–416. doi:10.1056/nejmoa2035389
  • Krammer F, Srivastava K, Alshammary H, Amoako AA, Awawda MH, Beach KF, et al. Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. N Engl J Med 2021;384(14):1372–1374. doi:10.1056/NEJMc2101667
  • Saadat S, Rikhtegaran Tehrani Z, Logue J, Newman M, Frieman MB, Harris AD, et al. Binding and neutralization antibody titers after a single vaccine dose in health care workers previously infected with SARS-CoV-2. JAMA 2021;325(14):1467–1469. doi:10.1001/jama.2021.3341
  • Published: 2021-06-04

    Issue: 2021: Vol 8 No 6 (view)

    Section: Articles

    How to cite:
    1.
    Sazgary L, Meienberg A, Berger CT, Mayr M. The Meaning of SARS-CoV-2 Antibodies in a Patient with a Systemic Reaction to the mRNA-1273 SARS-CoV-2 Vaccine after Previous Natural Immunization . EJCRIM 2021;8 doi:10.12890/2021_002617.